ChonlutenvsCrystagen

Molecular Formula

C₁₁H₁₇N₃O₈

Molecular Weight

319.27 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure

CAS Number

75007-24-8

Molecular Formula

C₁₄H₂₁N₃O₈

Molecular Weight

359.3 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure

CAS Number

Not assigned (patented as immunogeroprotective peptide, US8057810B2)

Common

• Injection site reaction
• Mild fatigue
• Transient respiratory changes
• Mild headache

Uncommon

• Flu-like symptoms

Serious

• No documented serious adverse effects

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Minor digestive changes

Uncommon

• Flu-like symptoms

Serious

• No documented serious adverse effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive pulmonary infections requiring immediate medical treatment
• xSevere immunosuppression without medical supervision — immunomodulatory effects may be unpredictable

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive autoimmune disease in flare without physician supervision
• xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens